IgA Nephropathy – Landscape & Forecast – Disease Landscape & Forecast
Immunoglobulin A nephropathy (IgAN), also known as Berger’s disease, is a rare autoimmune disease affecting the kidneys. It is characterized by predominant IgA protein deposition and impairment of blood filtration in the kidneys’ tiny blood channels. The IgAN drug market comprises supportive treatments such as antihypertensive drugs, immunosuppressants, and diuretics. The only approved therapy for IgAN is Tarpeyo (a delayed-release budesonide capsule). High unmet need exists for effective treatments that can meaningfully delay or halt this progressive end-stage kidney disease. The future of the IgAN market is bright owing to emerging therapies such as sparsentan (Travere Therapeutics), iptacopan (Novartis), narsoplimab (Omeros), atrasentan (Chinook Therapeutics), and sibeprenlimab (Otsuka). Supported by insights from thought leaders, we analyze the challenges and opportunities for new drugs to treat an increasingly dynamic and complex disease. Understanding the current and future competitive landscape is critical for marketers to secure market share and carve out a clinical niche.
Questions answered
- What is the diagnosed prevalence of IgAN populations? What percentage of the IgAN population receives drug treatment?
- What are the drivers and constraints in the IgAN market, and how will the market evolve through 2032?
- What is the current treatment landscape for IgAN? What are physicians’ experience and satisfaction levels with current key therapies?
- How are emerging therapies anticipated to influence the management of IgAN patients? What commercial impact will they have on the IgAN market?
- Which emerging therapies do experts consider most promising?
- What impact will sparsentan, forecast to be the first nonimmunosuppressive IgAN therapy, have on the treatment landscape?
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancements
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold. Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- IgA Nephropathy - Landscape & Forecast - Disease Landscape & Forecast
- Key Updates
- August 2023
- Key Findings
- IgA Nephropathy Key Findings - July 2023
- Market Outlook
- Key findings
- Market share of drug classes for IgA nephropathy: 2022
- Market share of drug classes for IgA nephropathy: 2032
- IgA nephropathy SWOT analysis
- Market drivers and constraints
- What factors are driving the market for IgA nephropathy?
- What factors are constraining the market for IgA nephropathy?
- Annual sales of drug classes for IgA nephropathy: 2022-2032
- Drug-class-specific trends
- Annual sales of RAAS inhibitors for IgA nephropathy in the major markets: 2022-2032
- Annual patient share of RAAS inhibitors in IgA nephropathy in the United States: 2022-2032
- Annual sales of RAAS inhibitors in IgA nephropathy in the United States: 2022-2032
- Annual patient share of RAAS inhibitors in IgA nephropathy in Europe: 2022-2032
- Annual sales of RAAS inhibitors in IgA nephropathy in Europe: 2022-2032
- Annual patient share of RAAS inhibitors in IgA nephropathy in Japan: 2022-2032
- Annual sales of RAAS inhibitors in IgA nephropathy in Japan: 2022-2032
- Annual sales of diuretics for IgA nephropathy in the major markets: 2022-2032
- Annual patient share of diuretics in IgA nephropathy in the United States: 2022-2032
- Annual sales of diuretics in IgA nephropathy in the United States: 2022-2032
- Annual patient share of diuretics in IgA nephropathy in Europe: 2022-2032
- Annual sales of diuretics in IgA nephropathy in Europe: 2022-2032
- Annual patient share of diuretics in IgA nephropathy in Japan: 2022-2032
- Annual sales of diuretics in IgA nephropathy in Japan: 2022-2032
- Annual sales of corticosteroids for IgA nephropathy in the major markets: 2022-2032
- Annual patient share of corticosteroids in IgA nephropathy in the United States: 2022-2032
- Annual sales of corticosteroids in IgA nephropathy in the United States: 2022-2032
- Annual patient share of corticosteroids in IgA nephropathy in Europe: 2022-2032
- Annual sales of corticosteroids in IgA nephropathy in Europe: 2022-2032
- Annual patient share of corticosteroids in IgA nephropathy in Japan: 2022-2032
- Annual sales of corticosteroids in IgA nephropathy in Japan: 2022-2032
- Annual sales of immunosuppressants for IgA nephropathy in the major markets: 2022-2032
- Annual patient share of immunosuppressants in IgA nephropathy in the United States: 2022-2032
- Annual sales of immunosuppressants in IgA nephropathy in the United States: 2022-2032
- Annual patient share of immunosuppressants in IgA nephropathy in Europe: 2022-2032
- Annual sales of immunosuppressants in IgA nephropathy in Europe: 2022-2032
- Annual patient share of immunosuppressants in IgA nephropathy in Japan: 2022-2032
- Annual sales of immunosuppressants in IgA nephropathy in Japan: 2022-2032
- Annual sales of SGLT-2 inhibitors for IgA nephropathy in the major markets: 2022-2032
- Annual patient share of SGLT-2 inhibitors in IgA nephropathy in the United States: 2022-2032
- Annual sales of SGLT-2 inhibitors in IgA nephropathy in the United States: 2022-2032
- Annual patient share of SGLT-2 inhibitors in IgA nephropathy in Europe: 2022-2032
- Annual sales of SGLT-2 inhibitors in IgA nephropathy in Europe: 2022-2032
- Annual patient share of SGLT-2 inhibitors in IgA nephropathy in Japan: 2022-2032
- Annual sales of SGLT-2 inhibitors in IgA nephropathy in Japan: 2022-2032
- Annual sales of endothelin and angiotensin II receptor antagonists in IgA nephropathy in the major markets: 2022-2032
- Annual patient share of endothelin and angiotensin II receptor antagonists in IgA nephropathy in the United States: 2022-2032
- Annual sales of endothelin and angiotensin II receptor antagonists in IgA nephropathy in the United States: 2022-2032
- Annual patient share of endothelin and angiotensin II receptor antagonists in IgA nephropathy in Europe: 2022-2032
- Annual sales of endothelin and angiotensin II receptor antagonists in IgA nephropathy in Europe: 2022-2032
- Annual patient share of endothelin and angiotensin II receptor antagonists in IgA nephropathy in Japan: 2022-2032
- Annual sales of endothelin and angiotensin II receptor antagonists in IgA nephropathy in Japan: 2022-2032
- Annual sales of endothelin receptor antagonists in IgA nephropathy in the major markets: 2022-2032
- Annual patient share of endothelin receptor antagonists in IgA nephropathy in the United States: 2022-2032
- Annual sales of endothelin receptor antagonists in IgA nephropathy in the United States: 2022-2032
- Annual patient share of endothelin receptor antagonists in IgA nephropathy in Europe: 2022-2032
- Annual sales of endothelin receptor antagonists in IgA nephropathy in Europe: 2022-2032
- Annual patient share of endothelin receptor antagonists in IgA nephropathy in Japan: 2022-2032
- Annual sales of endothelin receptor antagonists in IgA nephropathy in Japan: 2022-2032
- Annual sales of complement factor B inhibitors in IgA nephropathy in the major markets: 2022-2032
- Annual patient share of complement factor B inhibitors in IgA nephropathy in the United States: 2022-2032
- Annual sales of complement factor B inhibitors for IgA nephropathy in United States: 2022-2032
- Annual patient share of complement factor B inhibitors in IgA nephropathy in Europe: 2022-2032
- Annual sales of complement factor B inhibitor for IgA nephropathy in Europe: 2022-2032
- Annual patient share of complement factor B inhibitor in IgA nephropathy in Japan: 2022-2032
- Annual sales of complement factor B inhibitors in IgA nephropathy in Japan: 2022-2032
- Annual sales of MASP-2 inhibitors in IgA nephropathy in the major markets: 2022-2032
- Annual patient share of MASP-2 inhibitors in IgA nephropathy in the United States: 2022-2032
- Annual sales of MASP-2 inhibitors in IgA nephropathy in the United States: 2022-2032
- Annual patient share of MASP-2 inhibitors in IgA nephropathy in Europe: 2022-2032
- Annual sales of MASP2- inhibitors for IgA nephropathy in Europe: 2022-2032
- Annual patient share of MASP-2 inhibitors in IgA nephropathy in Japan: 2022-2032
- Annual sales of MASP-2 inhibitors in IgA nephropathy in Japan: 2022-2032
- Annual sales of APRIL and BLyS inhibitors in IgA nephropathy in the major markets: 2022-2032
- Annual patient share of APRIL and BLyS inhibitors in IgA nephropathy in the United States: 2022-2032
- Annual sales of APRIL and BLyS inhibitors in IgA nephropathy in the United States: 2022-2032
- Annual patient share of APRIL and BLyS inhibitors in IgA nephropathy in Europe: 2022-2032
- Annual sales of APRIL and BLyS inhibitors in IgA nephropathy in Europe: 2022-2032
- Annual patient share of APRIL and BLyS inhibitors in IgA nephropathy in Japan: 2022-2032
- Annual sales of APRIL and BLyS inhibitors in IgA nephropathy in Japan: 2022-2032
- Annual sales of APRIL inhibitors in IgA nephropathy in the major markets: 2022-2032
- Annual patient share of APRIL inhibitors in IgA nephropathy in the United States: 2022-2032
- Annual sales of APRIL inhibitors in IgA nephropathy in the United States: 2022-2032
- Annual patient share of APRIL inhibitors in IgA nephropathy in Europe: 2022-2032
- Annual sales of APRIL inhibitors in IgA nephropathy in Europe: 2022-2032
- Annual patient share of APRIL inhibitors in IgA nephropathy in Japan: 2022-2032
- Annual sales of APRIL inhibitors in IgA nephropathy in Japan: 2022-2032
- Key findings
- Forecast
- Market Forecast Assumptions
- Market Forecast Dashboard
- Etiology and Pathophysiology
- Disease overview
- Key genetic susceptibility loci in IgA nephropathy
- Key pathways and drug targets
- The pathogenesis of IgA nephropathy
- Key therapeutic targets
- Disease overview
- Epidemiology
- Key findings
- Epidemiology populations
- Disease definition, methods, and sources used
- Diagnosed incident cases of IgA nephropathy 2022-2032
- Disease definition, methods, and sources used
- Diagnosed lifetime prevalent cases of IgA nephropathy 2022-2032
- Drug-treated prevalent cases of IgA nephropathy: 2022-2032
- Key findings
- Current Treatment
- Key findings
- Treatment goals
- Key endpoints used in clinical trials for IgA nephropathy
- Key current therapies
- Overview
- Mechanism of action of key current classes used for IgA nephropathy
- Current treatments used for IgA nephropathy
- Market events impacting the use of key current therapies for IgA nephropathy
- Advantages and disadvantages of RAAS inhibitors
- Key ongoing clinical trials of RAAS inhibitors in the treatment of IgA nephropathy
- Expert insight: RAAS inhibitors
- Advantages and disadvantages of diuretics
- Key ongoing clinical trials of diuretics in the treatment of IgA nephropathy
- Expert insight: diuretics
- Advantages and disadvantages of corticosteroids
- Key ongoing clinical trials of corticosteroids in the treatment of IgA nephropathy
- Expert insight: corticosteroids
- Advantages and disadvantages of budesonide
- Key results from select clinical trials investigating Tarpeyo / Kinpeygo for the treatment of IgA nephropathy
- Key ongoing clinical trials of Tarpeyo / Kinpeygo (budesonide) in the treatment of IgA nephropathy
- Expert insights: budesonide
- Advantages and disadvantages of other immunosuppressants
- Key ongoing clinical trials of other immunosuppressants in the treatment of IgA nephropathy
- Expert insight: other immunosuppressants
- Advantages and disadvantages of SGLT-2 inhibitors
- Key results from select clinical trials investigating SGLT-2 inhibitors for the treatment of IgA nephropathy
- Key ongoing clinical trials of SGLT2 inhibitors in the treatment of IgA nephropathy
- Expert insight: SGLT-2 inhibitors
- Medical practice
- Overview
- Factors influencing drug selection in IgA nephropathy
- Treatment decision tree for IgA nephropathy: United States and Europe
- Treatment decision tree for IgA nephropathy: Japan
- Key findings
- Unmet Need Overview
- Current and future attainment of unmet needs in IgA nephropathy
- Top unmet needs in IgA nephropathy: current and future attainment
- Expert insight: unmet need in IgA nephropathy
- Drug Pipeline
- Pipeline
- Regulatory milestones
- Indication comparison
- Emerging Therapies
- Key findings
- Key emerging therapies
- Key therapies in development for IgA nephropathy
- Estimated launch dates of key emerging therapies for the treatment of IgA nephropathy
- Key results from select clinical trials investigating sparsentan for the treatment of IgA nephropathy
- Key ongoing clinical trials of sparsentan in the treatment of IgA nephropathy
- Analysis of the clinical development program for sparsentan
- Expert insight: sparsentan
- Expectations for launch and sales opportunity of sparsentan in IgA nephropathy
- Key results from select clinical trials investigating atrasentan for the treatment of IgA nephropathy
- Key ongoing clinical trials of atrasentan in the treatment of IgA nephropathy
- Analysis of the clinical development program for atrasentan
- Expert insight: atrasentan
- Expectations for launch and sales opportunity of atrasentan in IgA nephropathy
- Key results from select clinical trials investigating narsoplimab for the treatment of IgA nephropathy
- Key ongoing clinical trials of narsoplimab in the treatment of IgA nephropathy
- Analysis of the clinical development program for narsoplimab
- Expert insight: narsoplimab
- Expectations for launch and sales opportunity of narsoplimab in IgA nephropathy
- Iptacopan (LNP023)
- Key results from select clinical trials investigating iptacopan for the treatment of IgA nephropathy
- Key ongoing clinical trials of iptacopan in the treatment of IgA nephropathy
- Analysis of the clinical development program for iptacopan
- Expert insight: iptacopan
- Expectations for launch and sales opportunity of iptacopan in IgA nephropathy
- Key results from select clinical trials investigating IONIS-FB-LRx for the treatment of IgA nephropathy
- Key ongoing clinical trials of IONIS-FB-LRx in the treatment of IgA nephropathy
- Analysis of the clinical development program for IONIS FB LRx
- Expectations for launch and sales opportunity of IONIS-FB-LRx in IgA nephropathy
- Key results from select clinical trials investigating sibeprenlimab for the treatment of IgA nephropathy
- Key ongoing clinical trials of sibeprenlimab in the treatment of IgA nephropathy
- Analysis of the clinical development program for sibeprenlimab
- Expectations for launch and sales opportunity of sibeprenlimab in IgA nephropathy
- Key results from select clinical trials investigating BION-1301 for the treatment of IgA nephropathy
- Key ongoing clinical trials of BION-1301 in the treatment of IgA nephropathy
- Analysis of the clinical development program for BION-1301
- Expectations for launch and sales opportunity of BION-1301 in IgA nephropathy
- Key results from select clinical trials investigating atacicept for the treatment of IgA nephropathy
- Key ongoing clinical trials of atacicept in the treatment of IgA nephropathy
- Analysis of the clinical development program for atacicept
- Expectations for launch and sales opportunity of atacicept in IgA nephropathy
- Early-phase pipeline analysis
- Select compounds in early-phase development (Phase 1/2) for IgA nephropathy
- Key findings
- Access & Reimbursement Overview
- Region-specific reimbursement practices
- Key market access considerations in IgAN: United States
- General reimbursement environment: United States
- Key market access considerations in IgA nephropathy: EU5
- General reimbursement environment: EU5
- Key market access considerations in IgA nephropathy: Japan
- General reimbursement environment: Japan
- Region-specific reimbursement practices
- Appendix
- Abbreviations
- IgA nephropathy bibliography
- Key Updates
Karan Madhok, B.D.S., is an associate analyst on the Cardiovascular, Metabolic, Renal, and Hematologic Diseases team at Clarivate. Prior to joining this company, he worked in the intelligence and insight division of Prescient Healthcare Group. He has experience in various therapeutic domains, including rheumatology, immunology, oncology, and rare diseases, and has been extensively involved in client and project management. He holds a B.D.S. degree from Manipal College of Dental Sciences in Manipal, India.
Yogesh Shelke, M.B.A. (Pharm.), Manager, Cardiovascular, Metabolic, Renal, and Hematology. Before joining Clarivate, he was instrumental in providing actionable insights to clients from various leading pharmaceutical companies regarding competitive intelligence, market sizing and forecasting, pipeline analysis, situational analysis, unmet need analysis, and market entry strategies in a variety of therapeutic areas. He holds a bachelor’s degree in pharmacy from Pune University and a master’s degree in pharmaceutical marketing from the National Institute of Pharmaceutical Education and Research in Mohali, India.